about
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrenceSevere immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literatureRandomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).ESWL for difficult bile duct stones: a 15-year single centre experience.Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effectSerum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.High doses of ursodeoxycholic acid up-regulate the expression of placental breast cancer resistance protein in patients affected by intrahepatic cholestasis of pregnancyCurcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouseAntiinflammatory effect of phytosterols in experimental murine colitis model: prevention, induction, remission study.Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance.High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?Management of hepatic encephalopathy: focus on antibiotic therapy.Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.Proton pump inhibitors in cirrhosis: tradition or evidence based practice?Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project).Adverse effects of proton pump inhibitors.Ribavirin for chronic hepatitis C: and the mystery goes on.The pharmacological management of intrahepatic cholestasis of pregnancy.Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors.Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis.HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients.Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis.Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.The UDCA dosage deficit: a fate shared with CDCA.Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis.Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis.Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.Treatment with telbivudine for fulminant hepatitis B.Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response.Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: an emerging fungal agent.A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
P50
Q27490405-0EC51FD1-3305-4D8B-AE26-544D26AE29E9Q33424123-35B4F086-27CE-4462-B6B6-A8A8F929E92CQ33424900-187EC853-0706-477C-9CAE-E48FA2B9BB00Q34101982-D7AD511C-6D19-4F8A-B5F0-230A7FE0CBF9Q34416022-10D55FF3-B62A-4496-9819-FF60B09481ECQ34515631-1276A69D-4C55-4413-85F5-4463013A8E08Q34656891-F9C8C04C-689D-41FE-B301-0B11F5C248A1Q34745175-132E54DF-EE1B-4FFC-8C2F-BEFE6DCCDD95Q35049360-2E9E37F2-DF61-43D2-9502-A818EE79B498Q35288371-10D7CF37-BEAC-42C8-91AA-B5C8F5255A57Q35595775-E007D293-D38A-4C9C-8056-ACFD18F7BDA1Q35761342-C0DD3A51-76E8-468D-A3BD-14FB90E91A51Q36404952-8653007A-E95D-47F0-934A-A6D9B2A7A93AQ37118828-1739C48F-6E83-4751-8067-244A8C395799Q37169345-3FF821E8-C1B0-411A-AF27-F01BC8A77E46Q37347047-CDC62535-DCBC-406B-9062-EE3AAC040352Q37708650-89121C8C-1DD6-4DD5-8F2D-40764EC937A8Q37811184-75288A96-74C3-4B8A-984A-259F3CDAE547Q37847189-D4EB250A-2142-4046-A8D8-E933AEECA5B3Q38720561-87BA2A3A-90B5-41A1-9C45-206AD71C11CEQ38859081-6826A46B-15CD-4754-A7E1-736B0CA93A53Q39099624-74146449-4DA8-4626-A351-7EB091AE2AC4Q40634884-616C6EA5-53AD-4559-B232-FB54EAC9B843Q40869239-7A4A2EC1-24D0-4912-A9E6-672145CB5D7AQ41412082-F8249B16-157D-4F7F-956F-A2852C753C68Q41490866-3101CE50-847C-48A1-B4E2-6BF06D3B874CQ41654386-C792974E-ADA4-4557-80A3-91504BCE7D5EQ42192520-C1103E91-E0BA-4B73-9D45-940FA32F5545Q42249962-95A6C620-1BFD-42B1-AA3E-92ABE4A7E13BQ42979058-EF52189B-748A-4F2C-9C04-3C4741F96F22Q42980751-1689F9E6-B467-4626-958B-093BE4306A9EQ43036320-E68F09F0-1324-4343-8CAC-EF1C97B449BCQ43959635-1A4E2602-0266-4C86-9E51-01C15351D623Q44117701-7E5211D5-1389-4DA7-92C0-F04C1735C71DQ44139912-563F4845-0B14-4D2C-BB4D-8716BB6B7429Q44234283-030E9363-1D4B-4D88-B3C9-533EF86D3266Q44746506-31DA65E3-E3FE-4953-A6D2-CCAE12278058Q45156141-8D0ABB62-5204-4B77-B479-2311303C7ED2Q45244204-AC64F323-DAEA-49A3-B7D1-8FAB39C92F0FQ45415153-132662AC-CCEE-4EFE-923E-8F0D679014A0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giuseppe Mazzella
@ast
Giuseppe Mazzella
@en
Giuseppe Mazzella
@es
Giuseppe Mazzella
@nl
Giuseppe Mazzella
@sl
type
label
Giuseppe Mazzella
@ast
Giuseppe Mazzella
@en
Giuseppe Mazzella
@es
Giuseppe Mazzella
@nl
Giuseppe Mazzella
@sl
prefLabel
Giuseppe Mazzella
@ast
Giuseppe Mazzella
@en
Giuseppe Mazzella
@es
Giuseppe Mazzella
@nl
Giuseppe Mazzella
@sl
P106
P1153
7004882690
P21
P31
P496
0000-0001-8656-8112